Business Context and Reporting Period
This Form 8-K Current Report from Inmed Pharmaceuticals Inc. (INM) covers events occurring on June 3, 2026, and June 4, 2026. The Company is an emerging growth company incorporated in British Columbia, Canada, with its common shares listed on The Nasdaq Capital Market.
Key Financial Metrics
This filing does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on regulatory compliance status regarding stock listing requirements.
Material Changes
The primary material event is the resolution of a Nasdaq listing deficiency:
- Previous Deficiency: On March 27, 2026, Nasdaq notified the Company that its closing bid price was below the $1.00 minimum requirement for 30 consecutive trading days (February 11, 2026, to March 26, 2026).
- Resolution: On June 3, 2026, Nasdaq confirmed the Company regained compliance after maintaining a closing bid price at or above $1.00 per share for 10 consecutive business days (May 19, 2026, through June 2, 2026).
- Status: The listing matter is now closed.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operations, or discussion of new risks or contingencies beyond the resolved listing issue. The Company issued a press release on June 4, 2026, announcing the regained compliance.
Investor Verification Checklist
- Verify the current trading price of INM shares to ensure continued compliance with the $1.00 minimum bid price requirement.
- Review the press release filed as Exhibit 99.1 for any additional context on the stock price recovery.
- Monitor future filings for any new Nasdaq deficiency notices or other regulatory communications.